Trial · NCT04518293
Registered outcomes40
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 40 of 40
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Other | Percentage of Participants With a Serious Adverse Event (SAE) From Randomization to Week 12 | At Week 12 | The secondary safety outcome is the proportion of participants with at least one SAE from randomization to follow-up at Week 12. |
| Other | Percentage of Participants With Serious Adverse Event (SAE) From Randomization to Week 6 | Week 6 | The secondary safety outcome is the proportion of participants with at least one SAE from randomization to follow-up at Week 6. |
| Other | Percentage of Participants With Symptomatic Hypotension From Randomization to Week 12 | Week 12 | The secondary safety outcome is the proportion of participants who experienced at least one symptomatic hypotension episode from randomization to follow-up at Week 12. |
| Other | Percentage of Participants With Symptomatic Hypotension From Randomization to Week 6 | Week 6 | The secondary safety outcome is the proportion of participants who experienced at least one symptomatic hypotension episode from randomization to follow-up at Week 6. |
| Other | Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 12 | Week 12 | The secondary safety outcome is the proportion of participants with serum sodium \<135 mmol/L at follow-up Week 12. |
| Other | Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 6 | Week 6 | The secondary safety outcome is the proportion of participants with serum sodium \<135 mmol/L at follow-up Week 6. |
| Other | Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 12 | Week 12 | The secondary safety outcome is the proportion of participants with serum sodium \>145 mmol/L at follow-up Week 12. |
| Other | Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 6 | Week 6 | The secondary safety outcome is the proportion of participants with serum sodium \>145 mmol/L at follow-up Week 6. |
| Other | Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 12 | Week 12 | The secondary safety outcome is the proportion of participants with serum potassium concentration \<3.5 mmol/L at follow-up Week 12. |
| Other | Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 6 | Week 6 | The secondary safety outcome is the proportion of participants with serum potassium concentration below 3.5 mmol/l at follow-up Week 6. |
| Other | Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 12 | Week 12 | The secondary safety outcome is proportion of participants with serum potassium concentration \>5.5 mmol/l at follow-up Week 12. |
| Other | Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 6 | Week 6 | The secondary safety outcome is proportion of participants with serum potassium concentration \>5.5 mmol/L at follow-up Week 6. |
| Other | Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Drop of Over 30% From Randomization to Week 12 | Week 12 | The secondary safety outcome was the proportion of participants with an eGFR drop of over 30% from randomization to follow-up at Week 12. |
| Other | Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Drop of Over 30% From Randomization to Week 6 | Week 6 | The secondary safety outcome is the proportion of participants with an eGFR drop of over 30% from randomization to follow-up at Week 6. |
| Other | Percentage of Participants With Serum Sodium <135mmol/L or >145 mmol/L, and/or Serum Potassium <3.5 mmol/L or >5.5mmol/L at Follow-up Week 12 | Week 12 | The secondary safety outcome is the proportion of participants with serum sodium \<135mmol/L or \>145 mmol/L, and/or serum potassium \<3.5 mmol/L or \>5.5mmol/L at follow-up Week 12. |
| Other | Percentage of Participants With Serum Sodium <135 mmol/L or >145 mmol/L, and/or Serum Potassium <3.5 mmol/L or >5.5 mmol/L at Week 6 | Week 6 | The secondary safety outcome is proportion of participants with serum sodium \<135 mmol/L or \>145 mmol/L, and/or serum potassium \<3.5 mmol/L or \>5.5 mmol/L at follow-up Week 6. |
| Other | Percentage of Participants With Orthostatic Hypotension at Week 6 | Week 6 | The secondary safety outcome is the proportion of participants with orthostatic hypotension at follow-up Week 6. |
| Other | Percentage of Participants With Orthostatic Hypotension at Week 12 | Week 12 | The secondary safety outcome is the proportion of participants with orthostatic hypotension at follow-up Week 12. |
| Other | Percentage of Participants With Orthostatic Hypertension at Week 6 | Week 6 | The secondary safety outcome is the proportion of participants with orthostatic hypertension at follow-up Week 6. |
| Other | Percentage of Participants With Orthostatic Hypertension at Week 12 | Week 12 | The secondary safety outcome is the proportion of participants with orthostatic hypertension at follow-up Week 12. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04518293/registered?page=2